ArticleBiology direct2026
PAX5 alleviates atherosclerosis by transcriptionally regulating GSDMD and inhibiting STAT3-mediated pyroptosis.
Article in Biology direct, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveThis study aims to elucidate the role of PAX5 in the pathogenesis of atherosclerosis (AS) and its underlying mechanisms, with a particular focus on the transcriptional regulation of GSDMD and STAT3-mediated pyroptosis.
methodsSerum PAX5 and GSDMD levels were detected in AS patients and healthy controls. In vitro, human umbilical vein endothelial cells (HUVECs) were stimulated with oxidized low-density lipoprotein (ox-LDL) and transfected with PAX5 overexpression vectors, followed by assays for cell viability, tube formation, lipid accumulation, LDH release, and pro-inflammatory cytokine (IL-1β, IL-18) secretion. Immunofluorescence and dual-luciferase reporter assays were performed to verify the co-localization of PAX5 and GSDMD, and the transcriptional interaction between PAX5 and the GSDMD promoter. Co-immunoprecipitation (Co-IP) ubiquitination assays were conducted to determine whether PAX5 promotes GSDMD poly-ubiquitination. In vivo, ApoE⁻/⁻ AS mouse models were treated with AAV-mediated PAX5 overexpression, followed by histopathological assessment of atherosclerotic lesions, lipid metabolism detection, and Western blot analysis of pyroptosis and STAT3 signaling-related proteins.
resultsSerum PAX5 was significantly downregulated in AS patients, while GSDMD was upregulated. In vitro, PAX5 overexpression reversed ox-LDL-induced viability reduction, lipid accumulation, LDH release, and IL-1β/IL-18 hypersecretion in HUVECs. Dual-luciferase assay confirmed that PAX5 directly binds to and activates the GSDMD promoter. Ubiquitination assays demonstrated that PAX5 promotes both K48-linked and K63-linked poly-ubiquitination of GSDMD, with the degradation pathway predominating over transcriptional activation, resulting in a net decrease in GSDMD protein abundance. In vivo, PAX5 overexpression reduced atherosclerotic lesion size, lipid deposition, and systemic inflammatory levels, improved serum lipid profiles, and inhibited STAT3 phosphorylation, GSDMD-N generation, and pyroptosis-related protein expression.
conclusionPAX5 alleviates AS progression through a dual regulatory mechanism involving transcriptional activation and ubiquitin-proteasome-mediated degradation of GSDMD, thereby inhibiting STAT3-associated pyroptosis. PAX5 represents a promising therapeutic target for AS intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.